Moving low-risk myelodysplastic syndromes from humans to mice: is it truly that simple?

被引：0
|
作者：
Coriu, Daniel [1 ]
Stancioaica, Maria -Camelia [1 ]
机构：
[1] Carol Davila Univ Med & Pharm, Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 01期
关键词：
D O I：
10.3324/haematol.2023.283652
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8 / 10
页数：3
相关论文
共 50 条
  • [31] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.
    Sekeres, MA
    Fu, AZ
    Maciejewski, JP
    Golshayan, AR
    Kalaycio, M
    Kattan, MW
    BLOOD, 2005, 106 (11) : 711A - 711A
  • [32] Erythroid progenitors from patients with low-risk myelodysplastic syndromes are dependent on the surrounding micro environment for their survival
    Folkerts, Hendrik
    Hazenberg, Carin L. E.
    Houwerzijl, Ewout J.
    van den Heuvel, Fiona A. J.
    Mulder, Andre B.
    van der Want, Johannes J. L.
    Vellenga, Edo
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (03) : 215 - 222
  • [33] DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts
    Novotna, Bozena
    Neuwirtova, Radana
    Siskova, Magda
    Bagryantseva, Yana
    HUMAN MOLECULAR GENETICS, 2008, 17 (14) : 2144 - 2149
  • [34] ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES
    Cerchione, C.
    Martinelli, G.
    Soriente, I.
    D'Arco, A. M.
    Danise, P.
    Cerciello, G.
    Di Battista, V.
    Cangini, D.
    Giannini, M. B.
    Pane, F.
    Alfinito, F.
    HAEMATOLOGICA, 2019, 104 : 147 - 148
  • [35] DNA instability in low-risk myelodysplastic syndromes - refractory anemia with or without ring sideroblasts
    Novotna, B.
    Blazkova, V.
    Neuwirtova, R.
    Siskova, M.
    Bagryantseva, Y.
    LEUKEMIA RESEARCH, 2007, 31 : S72 - S72
  • [36] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Angel F. Remacha
    Beatriz Arrizabalaga
    Consuelo Del Cañizo
    Guillermo Sanz
    Ana Villegas
    Annals of Hematology, 2010, 89 : 147 - 154
  • [37] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Remacha, Angel F.
    Arrizabalaga, Beatriz
    Del Canizo, Consuelo
    Sanz, Guillermo
    Villegas, Ana
    ANNALS OF HEMATOLOGY, 2010, 89 (02) : 147 - 154
  • [38] Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes
    Patel, Bhumika
    Saygin, Caner
    Przychodzen, Bartlomiej P.
    Kuzmanovic, Teodora
    Hirsch, Cassandra M.
    Clemente, Michael J.
    Thota, Swapna
    Nazha, Aziz
    Mikkael, Sekeres A.
    Maciejewski, Jaroslaw P.
    Carraway, Hetty E.
    BLOOD, 2016, 128 (22)
  • [39] FLOW-CYTOMETRIC ASSESSMENT OF BONE MARROW MICROENVIRONMENT IN LOW-RISK MYELODYSPLASTIC SYNDROMES
    Giannotta, J. A.
    Fattizzo, B.
    Cro, L.
    Barbieri, M.
    Levati, G. V.
    Porretti, L.
    Barcellini, W.
    HAEMATOLOGICA, 2021, 106 (10) : 78 - 78
  • [40] Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response
    N. Viniou
    E. Terpos
    A. Galanopoulos
    E. Kritikou-Griva
    S. Akel
    E. Michalis
    E. Apostolidou
    D. Georgiadou
    A. Kouraklis
    A. Parharidou
    G. Kokkini
    A. Symeonidis
    N. Anagnostopoulos
    J. Christakis
    A. Tasiopoulou
    D. Loukopoulos
    X. Yataganas
    Annals of Hematology, 2002, 81 : 182 - 186
12345